Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 20 opinions in the last 12 months.
McKesson Corp (MCK) is recognized as a significant player in the healthcare distribution sector, boasting strong market share and growth potential driven by demographic trends such as an aging population. Various experts highlight its role as a distributor of both branded and generic drugs, noting that it stands to benefit from the rising demand for pharmaceuticals, particularly weight-loss drugs. The company is generally viewed as a steady performer, trading at reasonable price-to-earnings (PE) ratios relative to its growth rates, which are characterized as healthy. Some analysts express concerns about the low margins in drug distribution and potential headwinds related to US healthcare dynamics, yet many believe MCK remains a solid investment with a compelling long-term outlook. Furthermore, the stock's ability to navigate challenges in the healthcare landscape positions it well for future growth.
McKesson Corp is a American stock, trading under the symbol MCK-N on the New York Stock Exchange (MCK). It is usually referred to as NYSE:MCK or MCK-N
In the last year, 22 stock analysts published opinions about MCK-N. 16 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for McKesson Corp.
McKesson Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for McKesson Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
22 stock analysts on Stockchase covered McKesson Corp In the last year. It is a trending stock that is worth watching.
On 2025-05-16, McKesson Corp (MCK-N) stock closed at a price of $724.18.
Many attempts to lower drug prices in the US, and every one of them has failed. Very highly entrenched business to deconstruct. But stocks will rerate on the noise. So how much downside would there be to revenue?
He wouldn't buy this here. Tariffs and the drug noise have provided opportunities to expand in the healthcare space, which is very undervalued right now.